Clinical Trial Update: Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC [Phase 3]

View source ↗

Summary

Phase 3 study evaluating Eryaspase plus chemotherapy versus chemotherapy alone as second-line treatment for pancreatic adenocarcinoma has completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• Eryaspase (pegylated asparaginase)

Snippet

Sponsor: ERYtech Pharma | Conditions: Pancreatic Adenocarcinoma | Phase 3 | Status: COMPLETED | Results posted: 2022-09-28